ReviewJournal of central nervous system disease2014
Efficacy and side effects of natalizumab therapy in patients with multiple sclerosis.
Review in Journal of central nervous system disease, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach From the Writing Committee of the American Society for Apheresis: The Tenth Special Issue.Journal of clinical apheresis · 2026Guideline
- Trial
- Design and synthesis of novel small molecules targeting the Kv1.3 voltage-gated potassium ion channel.Scientific reports · 2025Article
- Monoclonal antibody precision therapy targeting inflammation for bipolar disorder: a narrative review.Therapeutic advances in psychopharmacology · 2024Review
- Article
- The novel HS-mimetic, Tet-29, regulates immune cell trafficking across barriers of the CNS during inflammation.Journal of neuroinflammation · 2023Article
- Decision Curve Analysis for Personalized Treatment Choice between Multiple Options.Medical decision making : an international journal of the Society for Medical Decision Making · 2023Article
- Review
- Natalizumab extended-interval dosing in multiple sclerosis to mitigate progressive multifocal leukoencephalopathy risk: initial study evidence and real-world experience.Journal of central nervous system disease · 2022Review
- A two-stage prediction model for heterogeneous effects of treatments.Statistics in medicine · 2021Article
- Review
- Paracellular and Transcellular Leukocytes Diapedesis Are Divergent but Interconnected Evolutionary Events.Genes · 2021Article
- Inflammatory bowel disease: Therapeutic limitations and prospective of the stem cell therapy.World journal of stem cells · 2020Review
- The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic.Multiple sclerosis and related disorders · 2020Review
- VLA-4 Expression and Activation in B Cell Malignancies: Functional and Clinical Aspects.International journal of molecular sciences · 2020Review
- A Case of Drug-Induced Liver Injury Secondary to Natalizumab.Case reports in hepatology · 2020Article
- Exploring the Association between Monoclonal Antibodies and Depression and Suicidal Ideation and Behavior: A VigiBase Study.Drug safety · 2019Article
- Is there a link between inflammation and fatigue in multiple sclerosis?Journal of inflammation research · 2018Review
- Real-World Lab Data in Natalizumab Treated Multiple Sclerosis Patients Up to 6 Years Long-Term Follow Up.Frontiers in neurology · 2018Article
- Differential effects of FTY720 on the B cell compartment in a mouse model of multiple sclerosis.Journal of neuroinflammation · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natalizumab (Nat) is a humanized monoclonal antibody used for the treatment of relapsing multiple sclerosis (MS). Nat inhibits lymphocyte migration via the blood brain barrier (BBB) by blockage of an integrin adhesion molecule, very late antigen 4. During the phase III clinical trials, it was shown that Nat reduces disease activity and prevents disability progression. In addition, several smaller studies indicate a positive influence of Nat on cognition, depression, fatigue, and quality of life (Qol). Therapeutic efficacy has to be weighed against the risk of developing potentially fatal progressive multifocal leukoencephalopathy (PML), an opportunistic infection by JC-virus (JCV) with an incidence of 3.4/1000 (95% CI 3.08-3.74) in Nat treated MS patients. In this review article, we will review data on the presumed mechanism of Nat action, clinical and paraclinical efficacy parameters, and adverse drug reactions with a special focus on PML.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.